F901318/0041 Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with invasive fungal disease (IFD) caused by Aspergillus s...
Lay Description
Category
- IRB Number
- 20220227HU
- NCT Number
- NCT # not yet entered
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Hillary Johnson
210-450-7612
johnsonh4@uthscsa.edu
Johnnie Jones
210-450-7277
jonesj21@uthscsa.edu
Irma Scholler
210-450-3150
scholler@uthscsa.edu
Principal Investigator
Thomas Patterson